Related Experiment Videos
Treatment of Alzheimer's disease: hopes and reality
S Gauthier1, L Gauthier, R Bouchard
1McGill Centre for Studies in Aging, Montreal, Quebec, Canada.
Abstract:
The relative failure of symptomatic therapeutic trials for Alzheimer's disease using non-selective cholinergic agonists brings about the need for longitudinal studies with parallel designs aimed at disease stabilization, using trophic substances or amyloid suppressors.
Insights
Symptomatic Alzheimer's disease treatments failed, necessitating new longitudinal studies. Future research should focus on disease stabilization using trophic factors or amyloid-suppressing therapies.
Area of Science:
- Neuroscience
- Pharmacology
- Gerontology
Background:
- Symptomatic treatments for Alzheimer's disease (AD) targeting cholinergic pathways have shown limited success.
- Non-selective cholinergic agonists have not effectively altered disease progression in AD clinical trials.
Purpose of the Study:
- To highlight the need for novel therapeutic strategies in Alzheimer's disease research.
- To advocate for longitudinal studies with parallel designs focused on disease stabilization.
Main Methods:
- Review of previous Alzheimer's disease symptomatic therapeutic trial outcomes.
- Conceptual framework for future longitudinal studies.
Main Results:
- Previous symptomatic therapeutic approaches for Alzheimer's disease have demonstrated relative failure.
- A shift towards disease-modifying strategies is indicated.
Conclusions:
- Longitudinal studies are crucial for evaluating disease stabilization in Alzheimer's disease.
- Future therapeutic interventions should explore trophic substances or amyloid suppressors to modify disease course.